Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EPS (Weighted Average and Diluted) (2018 - 2020)

Avai Bio's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at $0.02 for Q4 2020.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 882.96% to $0.02 in Q4 2020 year-over-year; TTM through Dec 2020 was $0.02, a 882.96% increase, with the full-year FY2020 number at -$0.07, down 305.46% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.02 in Q4 2020 for Avai Bio, up from -$0.0 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AVAI hit a ceiling of $0.02 in Q4 2020 and a floor of -$0.03 in Q3 2018.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.0 across 3 years, with a median of -$0.0 in 2019.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 77.97% in 2019 and later surged 882.96% in 2020.
  • Tracing AVAI's EPS (Weighted Average and Diluted) over 3 years: stood at -$0.0 in 2018, then surged by 48.07% to -$0.0 in 2019, then soared by 882.96% to $0.02 in 2020.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AVAI at $0.02 in Q4 2020, -$0.0 in Q3 2020, and $0.0 in Q2 2020.